Indivior reported robust Q3 2026 financial results, exceeding expectations with significant revenue and profit growth, driven by strong SUBLOCADE sales. The company also confirmed it is on track to close its merger with Supernus, indicating positive operational performance ahead of a major corporate event.
Indivior Pharmaceuticals reported a strong third quarter for 2026, with total net revenue up 13% year-over-year and record net income and adjusted EBITDA. This positive financial performance, particularly the 22% growth in SUBLOCADE revenue, indicates strong underlying business momentum. The confirmation that the company remains on track for its merger with Supernus on November 2, 2026, is a key piece of information, as it de-risks the upcoming corporate action. This news is positive for Indivior shareholders due to strong operational results and for Supernus shareholders as their future partner is performing well, potentially enhancing the combined entity's value. In the short term, this could lead to increased investor confidence and a positive price movement for both stocks. Long-term implications suggest a stronger combined entity post-merger, with potential for further growth and synergies.